A similar explanation may also apply to ZNRF3-mutant cancers of the endometrium and liver that also often show co-occurrence with other β-catenin activating mutations (Supplementary Table 1), while in other cancers such as melanomas and adrenocortical carcinomas the ZNRF3 mutation may be sufficient in itself. This evidence concerns the gene ZNRF3 and cancer.